Annual CFO
-$6.99 M
+$297.40 K+4.08%
30 June 2024
Summary:
InMed Pharmaceuticals annual cash flow from operations is currently -$6.99 million, with the most recent change of +$297.40 thousand (+4.08%) on 30 June 2024. During the last 3 years, it has risen by +$2.80 million (+28.65%). INM annual CFO is now -7051.04% below its all-time high of $100.50 thousand, reached on 30 June 2009.INM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.83 M
-$797.60 K-77.50%
30 September 2024
Summary:
InMed Pharmaceuticals quarterly cash flow from operations is currently -$1.83 million, with the most recent change of -$797.60 thousand (-77.50%) on 30 September 2024. Over the past year, it has increased by +$347.40 thousand (+15.98%). INM quarterly CFO is now -860.22% below its all-time high of $240.30 thousand, reached on 30 June 2005.INM Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$6.64 M
+$347.40 K+4.97%
30 September 2024
Summary:
InMed Pharmaceuticals TTM cash flow from operations is currently -$6.64 million, with the most recent change of +$347.40 thousand (+4.97%) on 30 September 2024. Over the past year, it has increased by +$563.40 thousand (+7.82%). INM TTM CFO is now -4622.07% below its all-time high of $146.80 thousand, reached on 30 September 2009.INM TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INM Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.1% | +16.0% | +7.8% |
| 3 y3 years | +28.6% | +31.2% | +40.0% |
| 5 y5 years | -4.6% | +22.8% | +13.9% |
INM Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +55.2% | -177.7% | +65.8% | -4.8% | +57.4% |
| 5 y | 5 years | -4.6% | +55.2% | -177.7% | +65.8% | -9.0% | +57.4% |
| alltime | all time | -7051.0% | +55.2% | -860.2% | +65.8% | -4622.1% | +57.4% |
InMed Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.83 M(+77.5%) | -$6.64 M(-5.0%) |
| June 2024 | -$6.99 M(-4.1%) | -$1.03 M(-46.8%) | -$6.99 M(+5.6%) |
| Mar 2024 | - | -$1.93 M(+4.7%) | -$6.61 M(+4.4%) |
| Dec 2023 | - | -$1.85 M(-15.0%) | -$6.34 M(-12.0%) |
| Sept 2023 | - | -$2.17 M(+230.5%) | -$7.20 M(-1.1%) |
| June 2023 | -$7.28 M(-53.3%) | -$657.90 K(-60.3%) | -$7.28 M(-31.8%) |
| Mar 2023 | - | -$1.66 M(-38.9%) | -$10.67 M(-25.7%) |
| Dec 2022 | - | -$2.71 M(+20.3%) | -$14.36 M(-5.4%) |
| Sept 2022 | - | -$2.26 M(-44.3%) | -$15.19 M(-2.6%) |
| June 2022 | -$15.58 M(+59.2%) | -$4.05 M(-24.3%) | -$15.58 M(+15.1%) |
| Mar 2022 | - | -$5.35 M(+51.4%) | -$13.54 M(+5.8%) |
| Dec 2021 | - | -$3.53 M(+33.2%) | -$12.81 M(+15.6%) |
| Sept 2021 | - | -$2.65 M(+32.3%) | -$11.07 M(+13.1%) |
| June 2021 | -$9.79 M(+32.8%) | -$2.01 M(-56.5%) | -$9.79 M(+6.6%) |
| Mar 2021 | - | -$4.61 M(+156.0%) | -$9.18 M(+50.7%) |
| Dec 2020 | - | -$1.80 M(+31.3%) | -$6.09 M(-4.5%) |
| Sept 2020 | - | -$1.37 M(-1.9%) | -$6.38 M(-13.5%) |
| June 2020 | -$7.37 M(+10.4%) | -$1.40 M(-8.1%) | -$7.37 M(-6.5%) |
| Mar 2020 | - | -$1.52 M(-27.2%) | -$7.89 M(-7.3%) |
| Dec 2019 | - | -$2.09 M(-11.6%) | -$8.51 M(+10.3%) |
| Sept 2019 | - | -$2.37 M(+23.5%) | -$7.71 M(+15.5%) |
| June 2019 | -$6.68 M(+88.0%) | -$1.91 M(-10.5%) | -$6.68 M(+16.0%) |
| Mar 2019 | - | -$2.14 M(+65.4%) | -$5.76 M(+34.0%) |
| Dec 2018 | - | -$1.29 M(-3.0%) | -$4.30 M(+13.2%) |
| Sept 2018 | - | -$1.33 M(+34.1%) | -$3.80 M(+6.9%) |
| June 2018 | -$3.55 M(+50.2%) | -$993.50 K(+46.7%) | -$3.55 M(+5.0%) |
| Mar 2018 | - | -$677.30 K(-14.7%) | -$3.38 M(-1.7%) |
| Dec 2017 | - | -$793.70 K(-27.0%) | -$3.44 M(+4.7%) |
| Sept 2017 | - | -$1.09 M(+32.0%) | -$3.29 M(+39.0%) |
| June 2017 | -$2.37 M(+512.6%) | -$824.40 K(+11.9%) | -$2.37 M(+44.6%) |
| Mar 2017 | - | -$736.90 K(+15.3%) | -$1.64 M(+70.6%) |
| Dec 2016 | - | -$639.20 K(+287.4%) | -$959.40 K(+126.4%) |
| Sept 2016 | - | -$165.00 K(+73.3%) | -$423.70 K(+9.7%) |
| June 2016 | -$386.10 K(-76.0%) | -$95.20 K(+58.7%) | -$386.10 K(-63.2%) |
| Mar 2016 | - | -$60.00 K(-42.0%) | -$1.05 M(-36.3%) |
| Dec 2015 | - | -$103.50 K(-18.8%) | -$1.65 M(+1.0%) |
| Sept 2015 | - | -$127.40 K(-83.2%) | -$1.63 M(+1.5%) |
| June 2015 | -$1.61 M(+150.6%) | -$759.60 K(+15.3%) | -$1.61 M(+8.1%) |
| Mar 2015 | - | -$658.70 K(+660.6%) | -$1.49 M(+79.7%) |
| Dec 2014 | - | -$86.60 K(-15.6%) | -$827.40 K(+11.6%) |
| Sept 2014 | - | -$102.60 K(-83.9%) | -$741.20 K(+15.6%) |
| June 2014 | -$641.40 K(+1532.1%) | -$638.80 K(<-9900.0%) | -$641.40 K(<-9900.0%) |
| Mar 2014 | - | $600.00(-250.0%) | $800.00(-27.3%) |
| Dec 2013 | - | -$400.00(-85.7%) | $1100.00(-107.7%) |
| Sept 2013 | - | -$2800.00(-182.4%) | -$14.20 K(-63.9%) |
| June 2013 | -$39.30 K | $3400.00(+277.8%) | -$39.30 K(-52.5%) |
| Mar 2013 | - | $900.00(-105.7%) | -$82.80 K(-18.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | - | -$15.70 K(-43.7%) | -$102.00 K(-37.2%) |
| Sept 2012 | - | -$27.90 K(-30.4%) | -$162.40 K(-7.0%) |
| June 2012 | -$174.60 K(-68.9%) | -$40.10 K(+119.1%) | -$174.60 K(-65.2%) |
| Mar 2012 | - | -$18.30 K(-76.0%) | -$501.40 K(-24.5%) |
| Dec 2011 | - | -$76.10 K(+89.8%) | -$664.00 K(+11.0%) |
| Sept 2011 | - | -$40.10 K(-89.1%) | -$598.30 K(+6.4%) |
| June 2011 | -$562.10 K(+187.7%) | -$366.90 K(+102.8%) | -$562.10 K(+129.3%) |
| Mar 2011 | - | -$180.90 K(+1639.4%) | -$245.10 K(+115.4%) |
| Dec 2010 | - | -$10.40 K(+166.7%) | -$113.80 K(-21.2%) |
| Sept 2010 | - | -$3900.00(-92.2%) | -$144.50 K(-26.0%) |
| June 2010 | -$195.40 K(-294.4%) | -$49.90 K(+0.6%) | -$195.40 K(-492.4%) |
| Mar 2010 | - | -$49.60 K(+20.7%) | $49.80 K(-34.6%) |
| Dec 2009 | - | -$41.10 K(-25.0%) | $76.20 K(-48.1%) |
| Sept 2009 | - | -$54.80 K(-128.1%) | $146.80 K(+46.2%) |
| June 2009 | $100.50 K(-110.6%) | $195.30 K(-941.8%) | $100.40 K(-120.2%) |
| Mar 2009 | - | -$23.20 K(-178.6%) | -$496.40 K(-7.4%) |
| Dec 2008 | - | $29.50 K(-129.2%) | -$536.30 K(-32.7%) |
| Sept 2008 | - | -$101.20 K(-74.8%) | -$796.90 K(-16.2%) |
| June 2008 | -$951.20 K(-31.8%) | -$401.50 K(+536.3%) | -$951.20 K(-20.6%) |
| Mar 2008 | - | -$63.10 K(-72.7%) | -$1.20 M(-10.3%) |
| Dec 2007 | - | -$231.10 K(-9.5%) | -$1.33 M(+15.2%) |
| Sept 2007 | - | -$255.50 K(-60.6%) | -$1.16 M(-16.9%) |
| June 2007 | -$1.40 M(+141.7%) | -$647.90 K(+223.6%) | -$1.40 M(+104.3%) |
| Mar 2007 | - | -$200.20 K(+262.0%) | -$683.10 K(-1.5%) |
| Dec 2006 | - | -$55.30 K(-88.8%) | -$693.30 K(-21.0%) |
| Sept 2006 | - | -$492.00 K(-864.0%) | -$877.20 K(+51.9%) |
| June 2006 | -$577.40 K(-17.8%) | $64.40 K(-130.6%) | -$577.40 K(+43.8%) |
| Mar 2006 | - | -$210.40 K(-12.0%) | -$401.50 K(+1.0%) |
| Dec 2005 | - | -$239.20 K(+24.5%) | -$397.70 K(-45.0%) |
| Sept 2005 | - | -$192.20 K(-180.0%) | -$722.70 K(+2.9%) |
| June 2005 | -$702.20 K(+45.0%) | $240.30 K(-216.3%) | -$702.20 K(-50.4%) |
| Mar 2005 | - | -$206.60 K(-63.4%) | -$1.42 M(-2.8%) |
| Dec 2004 | - | -$564.20 K(+228.6%) | -$1.46 M(+99.6%) |
| Sept 2004 | - | -$171.70 K(-63.8%) | -$730.30 K(+50.8%) |
| July 2004 | -$484.20 K(-42.7%) | -$474.60 K(+92.2%) | -$484.30 K(+58.5%) |
| Apr 2004 | - | -$246.90 K(-251.6%) | -$305.50 K(+22.1%) |
| Jan 2004 | - | $162.90 K(+119.2%) | -$250.30 K(-57.1%) |
| Oct 2003 | - | $74.30 K(-125.1%) | -$584.00 K(-30.9%) |
| July 2003 | -$844.60 K(-26.1%) | -$295.80 K(+54.3%) | -$844.60 K(+20.6%) |
| Apr 2003 | - | -$191.70 K(+12.2%) | -$700.20 K(-15.3%) |
| Jan 2003 | - | -$170.80 K(-8.3%) | -$826.70 K(-11.2%) |
| Oct 2002 | - | -$186.30 K(+23.1%) | -$930.80 K(-18.6%) |
| July 2002 | -$1.14 M(+142.4%) | -$151.40 K(-52.4%) | -$1.14 M(+15.3%) |
| Apr 2002 | - | -$318.20 K(+15.8%) | -$992.00 K(+47.2%) |
| Jan 2002 | - | -$274.90 K(-31.1%) | -$673.80 K(+68.9%) |
| Oct 2001 | - | -$398.90 K | -$398.90 K |
| July 2001 | -$471.70 K | - | - |
FAQ
- What is InMed Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals annual CFO year-on-year change?
- What is InMed Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals quarterly CFO year-on-year change?
- What is InMed Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals TTM CFO year-on-year change?
What is InMed Pharmaceuticals annual cash flow from operations?
The current annual CFO of INM is -$6.99 M
What is the all time high annual CFO for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high annual cash flow from operations is $100.50 K
What is InMed Pharmaceuticals annual CFO year-on-year change?
Over the past year, INM annual cash flow from operations has changed by +$297.40 K (+4.08%)
What is InMed Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of INM is -$1.83 M
What is the all time high quarterly CFO for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high quarterly cash flow from operations is $240.30 K
What is InMed Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, INM quarterly cash flow from operations has changed by +$347.40 K (+15.98%)
What is InMed Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of INM is -$6.64 M
What is the all time high TTM CFO for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high TTM cash flow from operations is $146.80 K
What is InMed Pharmaceuticals TTM CFO year-on-year change?
Over the past year, INM TTM cash flow from operations has changed by +$563.40 K (+7.82%)